MED1 and breast cancer: When the correlation between MED1 mRNA levels and BC prognosis was examined in patients using the TCGA (The Cancer Genome Atlas https://portal.gdc.cancer.gov/ (5 January 2022)) database, it was found that BC patients with high levels of MED1 mRNA had a poorer survival than patients with low levels of MED1 mRNA and it is more significant for those patients with ER+ BC [98].